| General Information |
| Business: |
Note: Aspargo Labs withdrew its plans for an NYSE Direct Listing in a letter to the SEC on July 29, 2026.The New York-based company filed plans for its NYSE Direct Listing on Jan. 10, 2025 – stating that registered stockholders planned to offer up to 177 million shares. The company did not update the prospectus after the initial filing.
We manufacture an erectile dysfunction drug in an oral liquid formulation.
|
| Industry: |
Pharmaceuticals |
| Employees: |
0 |
| Founded: |
|
| Contact Information |
| Address |
17 State Street, Suite 3220 New York, NY 10004 |
| Phone Number |
(646) 503-1260 |
| Web Address |
|
| View Prospectus: |
Aspargo Labs (Withdrawn) |
| Financial Information |
| Market Cap |
|
| Revenues |
$0.0 mil (last 12 months) |
| Net Income |
$0.0 mil (last 12 months) |
| IPO Profile |
| Symbol |
AAGO |
| Exchange |
NYSE |
| Shares (millions): |
0.0 |
| Price range |
$0.00 - $0.00 |
| Est. $ Volume |
$20.0 mil |
| Manager / Joint Managers |
TBA |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
Withdrawn |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
